Search

Your search keyword '"Brignier, A."' showing total 226 results
Start Over Author "Brignier, A."
226 results on '"Brignier, A."'

2. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

Author

Debureaux, Pierre-Edouard, Harel, Stéphanie, Parquet, Nathalie, Lemiale, Virginie, Siguret, Virginie, Goubeau, Laurie, Morin, Florence, Royer, Bruno, Cuccuini, Wendy, Elessa, Dikelele, Theves, Floriane, Brignier, Anne C, Azoulay, Elie, Arnulf, Bertrand, and Talbot, Alexis

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Rare Diseases, Clinical Research, Cancer, Hematology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Aged, Multiple Myeloma, Retrospective Studies, Prognosis, Bortezomib, Syndrome, Hematologic Diseases, HVS, myeloma, prognosis, TPE, neurological, Immunology, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

Hyperviscosity syndrome (HVS) is a rare complication of newly diagnosed multiple myeloma (NDMM) related to high tumour burden. Studies about the prognosis of HVS in modern-era therapy for NDMM are missing. We investigated a retrospective cohort study of NDMM with HVS between 2011-2021. Thirty-nine NDMM patients with HVS were included. HVS presentation was heterogeneous, with asymptomatic, mild, and neurological forms in 23%, 59%, and 18% of cases, respectively. No thrombosis or major bleeding was observed. Therapeutic plasma exchanges were used in 92% of patients, which were effective and well tolerated. No rebound effect was observed. All patients except one had at least one CRAB criterion. Most of the patients received bortezomib and high-dose steroids (95%) associated with an immunomodulatory drug (43%) or alkylating agents (42%). HVS in NDMM patients had dismal overall survival matched to multiple myeloma patient controls (without HVS) in our center (median: 3.6 vs. 7.7 years, p=0.01), as confirmed by multivariate analysis. Early deaths (in the first two months) occurred in 21% of older patients (>65 years). HVS in NDMM patients is a rare but life-threatening complication associated with high lethality in older patients and be a potential dismal prognosis factor in the modern treatment era.

Published
2022

3. Research priorities for therapeutic plasma exchange in critically ill patients

Author

Sascha David, Lene Russell, Pedro Castro, Andry van de Louw, Lara Zafrani, Tasneem Pirani, Nathan D. Nielsen, Eric Mariotte, Bruno L. Ferreyro, Jan T. Kielstein, Luca Montini, Anne C. Brignier, Matthias Kochanek, Joan Cid, Chiara Robba, Ignacio Martin-Loeches, Marlies Ostermann, Nicole P. Juffermans, and for the Nine-I investigators

Subjects
Knowledge, Gaps, Plasmapheresis, Expert panel, Apheresis, Research, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Abstract Therapeutic plasma exchange (TPE) is a therapeutic intervention that separates plasma from blood cells to remove pathological factors or to replenish deficient factors. The use of TPE is increasing over the last decades. However, despite a good theoretical rationale and biological plausibility for TPE as a therapy for numerous diseases or syndromes associated with critical illness, TPE in the intensive care unit (ICU) setting has not been studied extensively. A group of eighteen experts around the globe from different clinical backgrounds used a modified Delphi method to phrase key research questions related to “TPE in the critically ill patient”. These questions focused on: (1) the pathophysiological role of the removal and replacement process, (2) optimal timing of treatment, (3) dosing and treatment regimes, (4) risk–benefit assumptions and (5) novel indications in need of exploration. For all five topics, the current understanding as well as gaps in knowledge and future directions were assessed. The content should stimulate future research in the field and novel clinical applications.

Published
2023
Full Text
View/download PDF

4. Plasma exchange in the intensive care unit: a narrative review

Author

Bauer, Philippe R., Ostermann, Marlies, Russell, Lene, Robba, Chiara, David, Sascha, Ferreyro, Bruno L., Cid, Joan, Castro, Pedro, Juffermans, Nicole P., Montini, Luca, Pirani, Tasneem, Van De Louw, Andry, Nielsen, Nathan, Wendon, Julia, Brignier, Anne C., Schetz, Miet, Kielstein, Jan T., Winters, Jeffrey L., and Azoulay, Elie

Published
2022
Full Text
View/download PDF

5. The use of ICU resources in CAR-T cell recipients: a hospital-wide study

Author

Sandrine Valade, Michael Darmon, Lara Zafrani, Eric Mariotte, Virginie Lemiale, Swann Bredin, Guillaume Dumas, Nicolas Boissel, Florence Rabian, André Baruchel, Isabelle Madelaine, Jérôme Larghero, Anne Brignier, Etienne Lengliné, Stéphanie Harel, Bertrand Arnulf, Roberta Di Blasi, Catherine Thieblemont, and Elie Azoulay

Subjects
Anti-CD19 chimeric antigen receptor, Intensive care, Hematological malignancies, Sepsis, Performance status, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Abstract Background CAR-T cell (chimeric antigen receptor T) therapy has emerged as an effective treatment of refractory hematological malignancies. Intensive care management is intrinsic to CAR-T cell therapy. We aim to describe and to assess outcomes in critically ill CAR-T cell recipients. Study design and methods Hospital-wide retrospective study. Consecutive CAR-T cell recipients requiring ICU admission from July 2017 and December 2020 were included. Results 71 patients (median age 60 years [37–68]) were admitted to the ICU 6 days [4–7] after CAR-T cell infusion. Underlying malignancies included diffuse large B cell lymphoma (n = 53, 75%), acute lymphoblastic leukemia (17 patients, 24%) and multiple myeloma (n = 1, 1.45%). Performance status (PS) was 1 [1–2]. Shock was the main reason for ICU admission (n = 40, 48%). Isolated cytokine release syndrome (CRS) was the most common complication (n = 33, 46%), while 21 patients (30%) had microbiologically documented bacterial infection (chiefly catheter-related infection). Immune effector cell-associated neurotoxicity syndrome was reported in 26 (37%) patients. At ICU admission, vasopressors were required in 18 patients (25%) and invasive mechanical ventilation in two. Overall, 49 (69%) and 40 patients (56%) received tocilizumab or steroids, respectively. Determinant of mortality were the reason for ICU admission (disease progression vs. sepsis or CRS (HR 4.02 [95%CI 1.10–14.65]), Performance status (HR 1.97/point [95%CI 1.14–3.41]) and SOFA score (HR 1.16/point [95%CI 1.01–1.33]). Conclusions Meaningful survival could be achieved in up to half the CAR-T cell recipients. The severity of organ dysfunction is a major determinant of death, especially in patients with altered performance status or disease progression.

Published
2022
Full Text
View/download PDF

6. The use of ICU resources in CAR-T cell recipients: a hospital-wide study

Author

Valade, Sandrine, Darmon, Michael, Zafrani, Lara, Mariotte, Eric, Lemiale, Virginie, Bredin, Swann, Dumas, Guillaume, Boissel, Nicolas, Rabian, Florence, Baruchel, André, Madelaine, Isabelle, Larghero, Jérôme, Brignier, Anne, Lengliné, Etienne, Harel, Stéphanie, Arnulf, Bertrand, Di Blasi, Roberta, Thieblemont, Catherine, and Azoulay, Elie

Published
2022
Full Text
View/download PDF

7. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

Author

Rossignol, Julien, Ouedrani, Amani, Livideanu, Cristina Bulai, Barete, Stéphane, Terriou, Louis, Launay, David, Lemal, Richard, Greco, Celine, Frenzel, Laurent, Meni, Cecile, Bodemere-Skandalis, Christine, Polivka, Laura, Collange, Anne-Florence, Hachichi, Hassiba, Bouzourine, Sonia, Messaoud, Djazira Nait, Negretto, Mathilde, Vendrame, Laurence, Jambou, Marguerite, Gousseff, Marie, Durupt, Stéphane, Lega, Jean-Christophe, Durand, Jean-Marc, Gaudy, Caroline, Damaj, Gandhi, Gourin, Marie-Pierre, Hamidou, Mohamed, Bouillet, Laurence, Le Mouel, Edwige, Maria, Alexandre, Zunic, Patricia, Cabrera, Quentin, Vincent, Denis, Lavigne, Christian, Riviere, Etienne, Gourguechon, Clement, Courbebaisse, Marie, Lebeaux, David, Parfait, Béatrice, Friedlander, Gérard, Brignier, Anne, Lhermitte, Ludovic, Molina, Thierry Jo, Bruneau, Julie, Agopian, Julie, Dubreuil, Patrice, Ranta, Dana, Mania, Alexandre, Arock, Michel, Staropoli, Isabelle, Tournilhac, Olivier, Lortholary, Olivier, Schwartz, Olivier, Chatenoud, Lucienne, and Hermine, Olivier

Published
2022
Full Text
View/download PDF

8. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Author

Dourthe, Marie-Emilie, Rabian, Florence, Yakouben, Karima, Chevillon, Florian, Cabannes-Hamy, Aurélie, Méchinaud, Françoise, Grain, Audrey, Chaillou, Delphine, Rahal, Ilhem, Caillat-Zucman, Sophie, Lesprit, Emmanuelle, Naudin, Jérôme, Roupret-Serzec, Julie, Parquet, Nathalie, Brignier, Anne, Guérin-El Khourouj, Valérie, Lainey, Elodie, Caye-Eude, Aurélie, Cavé, Hélène, Clappier, Emmanuelle, Mathis, Stéphanie, Azoulay, Elie, Dalle, Jean Hugues, Dhédin, Nathalie, Madelaine, Isabelle, Larghero, Jérôme, Boissel, Nicolas, and Baruchel, André

Published
2021
Full Text
View/download PDF

9. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

Author

Pierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, Virginie Lemiale, Virginie Siguret, Laurie Goubeau, Florence Morin, Bruno Royer, Wendy Cuccuini, Dikelele Elessa, Floriane Theves, Anne C. Brignier, Elie Azoulay, Bertrand Arnulf, and Alexis Talbot

Subjects
HVS, myeloma, prognosis, TPE, neurological, Immunologic diseases. Allergy, RC581-607
Abstract

Hyperviscosity syndrome (HVS) is a rare complication of newly diagnosed multiple myeloma (NDMM) related to high tumour burden. Studies about the prognosis of HVS in modern-era therapy for NDMM are missing. We investigated a retrospective cohort study of NDMM with HVS between 2011-2021. Thirty-nine NDMM patients with HVS were included. HVS presentation was heterogeneous, with asymptomatic, mild, and neurological forms in 23%, 59%, and 18% of cases, respectively. No thrombosis or major bleeding was observed. Therapeutic plasma exchanges were used in 92% of patients, which were effective and well tolerated. No rebound effect was observed. All patients except one had at least one CRAB criterion. Most of the patients received bortezomib and high-dose steroids (95%) associated with an immunomodulatory drug (43%) or alkylating agents (42%). HVS in NDMM patients had dismal overall survival matched to multiple myeloma patient controls (without HVS) in our center (median: 3.6 vs. 7.7 years, p=0.01), as confirmed by multivariate analysis. Early deaths (in the first two months) occurred in 21% of older patients (>65 years). HVS in NDMM patients is a rare but life-threatening complication associated with high lethality in older patients and be a potential dismal prognosis factor in the modern treatment era.

Published
2022
Full Text
View/download PDF

10. Modalités de mobilisation des cellules souches hématopoïétiques autologues et objectifs cellulaires en cellules CD34 + : recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC)

Author

Brignier, Anne, Ader, Virginie, Bellegarde, Katia, Giraud, Christine, Guerout-Verite, Marie-Agnès, Hamzy, Fati, Huynh, Thi Ngoc Phuong, Levavasseur, Aurélie, Nacimento, Francisca, Rousseau, Yves, Vincent, Laure, Yakoub-Agha, Ibrahim, and De Vos, John

Published
2020
Full Text
View/download PDF

12. Allogreffe de cellules souches hématopoïétiques chez les patients adolescents et adultes atteints de drépanocytose

Author

Dhédin, N., primary, Vasseur, L., additional, Chevillon, F., additional, Jestin, M., additional, Flamarion, E., additional, Kamden, A., additional, Arnaud, C., additional, Genty, I., additional, Parquet, N., additional, Guitton, C., additional, Brignier, A., additional, Michaud, K., additional, Michaux, K., additional, Lagarde, M., additional, Peffault De Latour, R., additional, Bernit, E., additional, Boissel, N., additional, Arlet, J.B., additional, and Pondarré, C., additional

Published
2023
Full Text
View/download PDF

13. Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma

Author

Marianne Delville, Fabien Touzot, Chloé Couzin, Isabelle Hmitou, Lounes Djerroudi, Amani Ouedrani, François Lefrère, Caroline Tuchman-Durand, Chloé Mollet, Jean-Roch Fabreguettes, Nicolas Ferry, Laurent Laganier, Alessandra Magnani, Elisa Magrin, Valérie Jolaine, Asier Saez-Cirion, Orit Wolstein, Geoffrey Symonds, Pierre Frange, Hélène Moins-Teisserenc, Marie-Laure Chaix-Baudier, Antoine Toubert, Jérôme Larghero, Nathalie Parquet, Anne C. Brignier, Françoise Barré-Sinoussi, Eric Oksenhendler, and Marina Cavazzana

Subjects
Genetics, QH426-470, Cytology, QH573-671
Abstract

Although the risk of developing lymphoma has decreased in the highly active antiretroviral therapy era, this cancer remains the major cause of mortality in HIV-infected patients. Autologous hematopoietic stem cell transplantation (ASCT) outcome does not differ for HIV-infected versus HIV-uninfected patients. We propose to develop a new treatment for HIV-associated high-risk lymphoma based on autologous transplantation of two genetically modified products: CD4+ T lymphocytes and CD34+ hematopoietic stem cells (HSPCs). The cells will be transduced ex vivo with the Cal-1 lentiviral vector encoding for both a short hairpin RNA (shRNA) against CCR5 (sh5) and the HIV-1 fusion inhibitor C46. The transduced cells will be resistant to HIV infection by two complementary mechanisms: impaired binding of the virus to the cellular CCR5 co-receptor and decreased fusion of the virus as C46 interacts with gp41 and inhibits HIV infection. This phase I/II pilot study, also entitled GENHIV, will involve two French participating centers: Saint Louis Hospital and Necker Hospital in Paris. We plan to enroll five HIV-1-infected patients presenting with high-risk lymphoma and require a treatment with ASCT. The primary objective of this study is to evaluate the safety, feasibility, and success of engraftment of Cal-1 gene-transduced CD4+ T lymphocytes and CD34+ HSPCs.

Published
2019
Full Text
View/download PDF

15. Research priorities for therapeutic plasma exchange in critically ill patients

Author

David, Sascha; https://orcid.org/0000-0002-8231-0461, Russell, Lene, Castro, Pedro, van de Louw, Andry, Zafrani, Lara, Pirani, Tasneem, Nielsen, Nathan D, Mariotte, Eric, Ferreyro, Bruno L, Kielstein, Jan T, Montini, Luca, Brignier, Anne C, Kochanek, Matthias, Cid, Joan, Robba, Chiara, Martin-Loeches, Ignacio, Ostermann, Marlies, Juffermans, Nicole P, David, Sascha; https://orcid.org/0000-0002-8231-0461, Russell, Lene, Castro, Pedro, van de Louw, Andry, Zafrani, Lara, Pirani, Tasneem, Nielsen, Nathan D, Mariotte, Eric, Ferreyro, Bruno L, Kielstein, Jan T, Montini, Luca, Brignier, Anne C, Kochanek, Matthias, Cid, Joan, Robba, Chiara, Martin-Loeches, Ignacio, Ostermann, Marlies, and Juffermans, Nicole P

Abstract

Therapeutic plasma exchange (TPE) is a therapeutic intervention that separates plasma from blood cells to remove pathological factors or to replenish deficient factors. The use of TPE is increasing over the last decades. However, despite a good theoretical rationale and biological plausibility for TPE as a therapy for numerous diseases or syndromes associated with critical illness, TPE in the intensive care unit (ICU) setting has not been studied extensively. A group of eighteen experts around the globe from different clinical backgrounds used a modified Delphi method to phrase key research questions related to “TPE in the critically ill patient”. These questions focused on: (1) the pathophysiological role of the removal and replacement process, (2) optimal timing of treatment, (3) dosing and treatment regimes, (4) risk–benefit assumptions and (5) novel indications in need of exploration. For all five topics, the current understanding as well as gaps in knowledge and future directions were assessed. The content should stimulate future research in the field and novel clinical applications.

Published
2023

17. Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Author

Laurence Legros, Françoise Boyer perrard, Dana Ranta, Lydia Roy, Mario Ojeda-Uribe, Stephane Giraudier, Nathalie Parquet, Jean Christophe Ianotto, Mathieu Wemeau, Isabelle Plantier, Franck E. Nicolini, Eric Lippert, Pascale Cony-Makhoul, Fiorenza Barraco, Laure Stalnikiewicz, Frederic Garban, Brigitte Dupriez, Francois Girodon, Anne Brignier, Yazid Arkam, Mathieu Meunier, Chloe James, Valérie Rolland-Neyret, Valerie Ugo, Pierre Morel, Marie C Bene, and Jean-Jacques Kiladjian

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

19. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

Author

Debureaux, Pierre-Edouard, primary, Harel, Stéphanie, additional, Parquet, Nathalie, additional, Lemiale, Virginie, additional, Siguret, Virginie, additional, Goubeau, Laurie, additional, Morin, Florence, additional, Royer, Bruno, additional, Cuccuini, Wendy, additional, Elessa, Dikelele, additional, Theves, Floriane, additional, Brignier, Anne C., additional, Azoulay, Elie, additional, Arnulf, Bertrand, additional, and Talbot, Alexis, additional

Published
2022
Full Text
View/download PDF

20. Additional file 1 of Research priorities for therapeutic plasma exchange in critically ill patients

Author

David, Sascha, Russell, Lene, Castro, Pedro, van de Louw, Andry, Zafrani, Lara, Pirani, Tasneem, Nielsen, Nathan D., Mariotte, Eric, Ferreyro, Bruno L., Kielstein, Jan T., Montini, Luca, Brignier, Anne C., Kochanek, Matthias, Cid, Joan, Robba, Chiara, Martin-Loeches, Ignacio, Ostermann, Marlies, and Juffermans, Nicole P.

Abstract

Additional file 1: Table S1. Expert panel composition. Table S2. ASFA recommendations for explorative indicationsadopted from Schwartz et al. [76].

Published
2023
Full Text
View/download PDF

23. Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

Author

Debureaux, Pierre-Edouard, primary, Harel, Stephanie, additional, Parquet, Nathalie, additional, Lemiale, Virginie, additional, Siguret, Virginie, additional, Goubeau, Laurie, additional, Morin, Florence, additional, Royer, Bruno, additional, Cuccuini, Wendy, additional, Elessa, Dikelele, additional, Theves, Floriane, additional, Brignier, Anne, additional, Azoulay, Elie, additional, Arnulf, Bertrand, additional, and Talbot, Alexis, additional

Published
2022
Full Text
View/download PDF

24. Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Author

Legros, Laurence, primary, Boyer perrard, Françoise, additional, Ranta, Dana, additional, Roy, Lydia, additional, Ojeda-Uribe, Mario, additional, Giraudier, Stephane, additional, Parquet, Nathalie, additional, Ianotto, Jean Christophe, additional, Wemeau, Mathieu, additional, Plantier, Isabelle, additional, Nicolini, Franck E., additional, Lippert, Eric, additional, Cony-Makhoul, Pascale, additional, Barraco, Fiorenza, additional, Stalnikiewicz, Laure, additional, Garban, Frederic, additional, Dupriez, Brigitte, additional, Girodon, Francois, additional, Brignier, Anne, additional, Arkam, Yazid, additional, Meunier, Mathieu, additional, James, Chloe, additional, Rolland-Neyret, Valérie, additional, Ugo, Valerie, additional, Morel, Pierre, additional, Bene, Marie C, additional, and Kiladjian, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

25. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

Author

Cuffel, Alexis, primary, Allain, Vincent, additional, Faivre, Lionel, additional, Di Blasi, Roberta, additional, Morin, Florence, additional, Vercellino, Laetitia, additional, Chevalier, Mathieu F., additional, Desnoyer, Aude, additional, de Jorna, Romain, additional, Madelaine, Isabelle, additional, Parquet, Nathalie, additional, Brignier, Anne C., additional, Thieblemont, Catherine, additional, Larghero, Jerome, additional, Caillat-Zucman, Sophie, additional, and Mebarki, Miryam, additional

Published
2022
Full Text
View/download PDF

27. Plasma exchange in the intensive care unit: a narrative review

Author

Bauer, P.R., Ostermann, M., Russell, L., Robba, C., David, S., Ferreyro, B.L., Cid, J., Castro, P., Juffermans, N.P., Montini, L., Pirani, T., Louw, A. van de, Nielsen, N., Wendon, J., Brignier, A.C., Schetz, M., Kielstein, J.T., Pickkers, P., Hemelaar, P., Winters, J.L., Azoulay, E., Bauer, P.R., Ostermann, M., Russell, L., Robba, C., David, S., Ferreyro, B.L., Cid, J., Castro, P., Juffermans, N.P., Montini, L., Pirani, T., Louw, A. van de, Nielsen, N., Wendon, J., Brignier, A.C., Schetz, M., Kielstein, J.T., Pickkers, P., Hemelaar, P., Winters, J.L., and Azoulay, E.

Abstract

Item does not contain fulltext, In this narrative review, we discuss the relevant issues of therapeutic plasma exchange (TPE) in critically ill patients. For many conditions, the optimal indication, device type, frequency, duration, type of replacement fluid and criteria for stopping TPE are uncertain. TPE is a potentially lifesaving but also invasive procedure with risk of adverse events and complications and requires close monitoring by experienced teams. In the intensive care unit (ICU), the indications for TPE can be divided into (1) absolute, well-established, and evidence-based, for which TPE is recognized as first-line therapy, (2) relative, for which TPE is a recognized second-line treatment (alone or combined) and (3) rescue therapy, where TPE is used with a limited or theoretical evidence base. New indications are emerging and ongoing knowledge gaps, notably regarding the use of TPE during critical illness, support the establishment of a TPE registry dedicated to intensive care medicine.

Published
2022

28. Plasma exchange in the intensive care unit: a narrative review

Author

R Bauer, Philippe, Ostermann, Marlie, Russell, Lene, Robba, Chiara, L Ferreyro, Sascha David Bruno, Cid, Joan, Castro, Pedro, P Juffermans, Nicole, Montini, Luca, Pirani, Tasneem, Van De Louw, Andry, Nielsen, Nathan, Wendon, Julia, C Brignier, Anne, Schetz, Miet, T Kielstein, Jan, L Winters, Jeffrey, Azoulay, Elie, Investigators, Nine-I, Luca Montini (ORCID:0000-0003-4602-5134), R Bauer, Philippe, Ostermann, Marlie, Russell, Lene, Robba, Chiara, L Ferreyro, Sascha David Bruno, Cid, Joan, Castro, Pedro, P Juffermans, Nicole, Montini, Luca, Pirani, Tasneem, Van De Louw, Andry, Nielsen, Nathan, Wendon, Julia, C Brignier, Anne, Schetz, Miet, T Kielstein, Jan, L Winters, Jeffrey, Azoulay, Elie, Investigators, Nine-I, and Luca Montini (ORCID:0000-0003-4602-5134)

Abstract

In this narrative review, we discuss the relevant issues of therapeutic plasma exchange (TPE) in critically ill patients. For many conditions, the optimal indication, device type, frequency, duration, type of replacement fluid and criteria for stopping TPE are uncertain. TPE is a potentially lifesaving but also invasive procedure with risk of adverse events and complications and requires close monitoring by experienced teams. In the intensive care unit (ICU), the indications for TPE can be divided into (1) absolute, well-established, and evidence-based, for which TPE is recognized as first-line therapy, (2) relative, for which TPE is a recognized second-line treatment (alone or combined) and (3) rescue therapy, where TPE is used with a limited or theoretical evidence base. New indications are emerging and ongoing knowledge gaps, notably regarding the use of TPE during critical illness, support the establishment of a TPE registry dedicated to intensive care medicine.

Published
2022

29. APRIL levels are associated with disease activity in human chronic graft-versus-host disease

Author

François Chasset, Adèle de Masson, Hélène Le Buanec, Aliénor Xhaard, Flore Sicre de Fontbrune, Marie Robin, Michel Rybojad, Nathalie Parquet, Anne C. Brignier, Tereza Coman, Djaouida Bengoufa, Anne Bergeron, Régis Peffault de Latour, Martine Bagot, Armand Bensussan, Gérard Socié, and Jean-David Bouaziz

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2016
Full Text
View/download PDF

30. Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation

Author

Flore Sicre de Fontbrune, Camilla Frieri, Simona Pagliuca, Marie Robin, Aliénor Xhaard, Gérard Socié, Pedro Henrique Prata, Régis Peffault de Latour, David Michonneau, Nathalie Dhedin, Aurélien Sutra Del Galy, Anne Brignier, and Livia Giannoni

Subjects
Transplantation, medicine.medical_specialty, business.industry, medicine.medical_treatment, chemical and pharmacologic phenomena, Retrospective cohort study, Hematology, Hematopoietic stem cell transplantation, Disease, medicine.disease, Gastroenterology, Regimen, surgical procedures, operative, Graft-versus-host disease, immune system diseases, In vivo, Internal medicine, Medicine, Risk factor, business, Complication
Abstract

Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory GVHD in a large cohort of 1207 patients receiving HSCT in Saint Louis Hospital between 2007 and 2017. Among patients who developed an acute and/or a chronic GVHD, the cumulative incidences of acute and chronic steroid-refractory disease were 31% and 48%, respectively, at day +100 and 1-year post-HSCT. Through a multivariable analysis we selected several risk factors associated with the development of a steroid-refractory disease. For acute GVHD steroid refractoriness, we identified (1) a very high disease risk index, (2) an unrelated donor, (3) the absence of in vivo T-depletion as GVHD prophylaxis, and (4) a reduced intensity conditioning regimen. For chronic GVHD, (1) the use of peripheral blood stem cells, (2) unrelated donors, and (3) absence of in vivo T-depletion were more likely associated with a steroid-refractory disease. After the construction of a multistate dynamic model, we found that the probability of being alive without relapse after the resolution of all GVHD episodes was about 36% in the long term.

Published
2020

31. Modalités de mobilisation des cellules souches hématopoïétiques autologues et objectifs cellulaires en cellules CD34 + : recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC)

Author

Fati Hamzy, Laure Vincent, Anne Brignier, Christine Giraud, Thi Ngoc Phuong Huynh, Francisca Nacimento, Aurélie Levavasseur, Virginie Ader, John De Vos, Katia Bellegarde, Marie-Agnès Guerout-Verite, Yves Rousseau, Ibrahim Yakoub-Agha, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Royal Victoria Hospital, McGill University Health Center [Montreal] (MUHC), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Etablissement français du sang [Poitiers] (EFS), Etablissement français du sang [Rennes] (EFS Bretagne), Université Internationale Abulcasis des Sciences de la Santé (UIASS), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Unité de Recherches sur la Génétique des Protéines Humaines [Bois-Guillaume] (U78 INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Département d'hématologie biologique[Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Lille, Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and CCSD, Accord Elsevier

Subjects
Cancer Research, medicine.medical_specialty, MESH: Heterocyclic Compounds, Bone marrow transplantation, medicine.medical_treatment, Autogreffe de cellules souches, Mobilization, MESH: Algorithms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematopoietic stem cell transplantation, Autologous stem cell transplantation, 030204 cardiovascular system & hematology, MESH: Cell Separation, Cellules souches hématopoïétiques, MESH: Hematopoietic Stem Cell Mobilization, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Risk Factors, Cell dose, medicine, Autologous transplantation, Radiology, Nuclear Medicine and imaging, MESH: Hematopoietic Cell Growth Factors, MESH: Hematopoietic Stem Cell Transplantation, Mobilisation, Gynecology, MESH: Humans, MESH: Cell Count, business.industry, Plerixafor, MESH: Antigens, CD34, Hematology, General Medicine, MESH: Transplantation, Autologous, MESH: Blood Component Removal, Oncology, MESH: Practice Patterns, Physicians', MESH: Antineoplastic Agents, MESH: Bone Marrow, MESH: Granulocyte Colony-Stimulating Factor, Stem cell, business, Hematopoietic stem cells, 030215 immunology, medicine.drug
Abstract

The modalities of mobilization of hematopoietic stem cells in autologous transplantation have evolved in recent years. The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 9th hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2018 in Lille, France, to conduct a review of current practices of the society centers and of international recommendations. The cell dose objectives have been revised. The modalities of mobilization including the use of plerixafor have been specified allowing reaching the objectives of collection while limiting the number of apheresis. Collections failures have become exceptional., Les modalités de mobilisation des cellules souches hématopoïétiques dans le cadre de la greffe autologue ont évolué ces dernières années. Dans le cadre des neuvièmes Ateliers d’harmonisation des pratiques en greffe de cellules souches hématopoïétiques de la Société Francophone de Greffe de Mœlle et de Thérapie Cellulaire (SFGM-TC) qui ont eu lieu à Lille en septembre 2018, un groupe de travail s’est réuni dans le but de réaliser un état des lieux des pratiques des centres de la société et des recommandations internationales. Les objectifs de richesse des greffons ont été revus à la hausse. Les modalités de mobilisation, y compris d’utilisation du plerixafor, ont été précisées, dans l’objectif d’atteindre les objectifs de recueil tout en limitant le nombre de cytaphérèses. Les échecs de recueils sont devenus exceptionnels.

Published
2020

32. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

Author

Alexis Cuffel, Vincent Allain, Lionel Faivre, Roberta Di Blasi, Florence Morin, Laetitia Vercellino, Mathieu F. Chevalier, Aude Desnoyer, Romain de Jorna, Isabelle Madelaine, Nathalie Parquet, Anne C. Brignier, Catherine Thieblemont, Jerome Larghero, Sophie Caillat-Zucman, Miryam Mebarki, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Université Paris-Saclay, Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), and leboeuf, Christophe

Subjects
Lymphoma, B-Cell, [SDV.CAN] Life Sciences [q-bio]/Cancer, T-Lymphocytes, Blood Component Removal, Receptors, Antigen, T-Cell, Humans, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology
Abstract

International audience; No abstract available

Published
2022

33. Additional file 1 of The use of ICU resources in CAR-T cell recipients: a hospital-wide study

Author

Valade, Sandrine, Darmon, Michael, Zafrani, Lara, Mariotte, Eric, Lemiale, Virginie, Bredin, Swann, Dumas, Guillaume, Boissel, Nicolas, Rabian, Florence, Baruchel, André, Madelaine, Isabelle, Larghero, Jérôme, Brignier, Anne, Lengliné, Etienne, Harel, Stéphanie, Arnulf, Bertrand, Di Blasi, Roberta, Thieblemont, Catherine, and Azoulay, Elie

Abstract

Additional file1: Figure S1. Patient flow chart. Table S1. CRS grading (adapted from Lee et al, Biol Blood Marrow Transplant 2019). Table S2. Neurotoxicity grading according to the CAR-T cell therapy-associated TOXicity score (CARTOX) (adapted from Lee et al, Biol Blood Marrow Transplant 2019). Table S3. Variables associated with mortality by multivariable logistic regression. Table S4. Causes of death

Published
2022
Full Text
View/download PDF

34. Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response

Author

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, David Launay, Richard Lemal, Celine Greco, Laurent Frenzel, Cecile Meni, Christine Bodemere-Skandalis, Laura Polivka, Anne-Florence Collange, Hassiba Hachichi, Sonia Bouzourine, Djazira Nait Messaoud, Mathilde Negretto, Laurence Vendrame, Marguerite Jambou, Marie Gousseff, Stéphane Durupt, Jean-Christophe Lega, Jean-Marc Durand, Caroline Gaudy, Gandhi Damaj, Marie-Pierre Gourin, Mohamed Hamidou, Laurence Bouillet, Edwige Le Mouel, Alexandre Maria, Patricia Zunic, Quentin Cabrera, Denis Vincent, Christian Lavigne, Etienne Riviere, Clement Gourguechon, Anne Brignier, Ludovic Lhermitte, Thierry Jo Molina, Julie Bruneau, Julie Agopian, Patrice Dubreuil, Dana Ranta, Alexandre Mania, Michel Arock, Isabelle Staropoli, Olivier Tournilhac, Olivier Lortholary, Olivier Schwartz, Lucienne Chatenoud, and Olivier Hermine

Subjects
education.field_of_study, Innate immune system, biology, business.industry, ELISPOT, Population, Tryptase, Acquired immune system, Immune system, Immunity, Immunology, biology.protein, Medicine, Antibody, education, business
Abstract

Mast cells are key actors of innate immunity and Th2 adaptive immune response which counterbalance Th1 response, critical for anti-viral immunity. Clonal Mast Cells Activation Disorders (cMCADs) such as mastocytosis and clonal mast cells activation syndrome are characterized by an abnormal mast cells accumulation and/or activation. No data have been published on the anti-viral immune response of patients with cMCADs. The aims of the study were to collected, in a comprehensive way, outcomes of cMCADs patients who experienced a biologically-proven COVID-19 and to characterize both anti-endemic coronaviruses and specific anti-SARS-CoV-2 immune responses in these patients. Clinical follow-up and outcome data were collected prospectively for one year within the French rare disease network CEREMAST encompassing patients from all over the country. Anti-SARS-CoV-2 and anti-endemic coronaviruses specific T-cells were assessed with an enzyme-linked immunospot assay (EliSpot) and anti-SARS-CoV-2 humoral response with dosage of circulating levels of specific IgG, IgA and neutralizing antibodies. Overall, 32 cMCADs patients were identified. None of them required non-invasive or mechanical ventilation; two patients were hospitalized to receive oxygen and steroid therapy. In 21 patients, a characterization of the SARS-CoV-2-specific immune response has been performed. A majority of patients showed a high proportion of circulating SARS-CoV-2-specific interferon (IFN)-γ producing T-cells and high levels of anti-Spike IgG antibodies with neutralizing activity. In addition, no defects in anti-endemic coronaviruses responses were found in patients with cMCADs compared to non-cMCADs controls. Patients with cMCADs frequently showed a spontaneous IFN-γ T-cell production in absence of any stimulation that correlated with circulating basal tryptase levels, a marker of mast cells burden. These findings underscore that patients with cMCADs might be not at risk of severe COVID-19 and the spontaneous IFN-γ production might explain this observation.Author SummaryMast cells are immune cells involved in many biological processes including the anti-microbial response. However, previous studies suggest that mast cells may have a detrimental role in the response against viruses such as SARS-CoV-2, responsible for COVID-19. When a mutation occurs in mast cells, it can lead to a group of diseases called clonal mast cells activation disorders (cMCADs), characterized by deregulated activation of these cells. Hence, patients with cMCADs might be more susceptible to severe COVID-19 than general population.We therefore conducted a 1-year study in France to collect data from all cMCADs patients included in the CEREMAST rare disease French network and who experienced COVID-19. Interestingly, we did not find any severe COVID-19 (i.e. requiring non-invasive or mechanical ventilation) in spite of well-known risk factors for severe COVID-19 in a part of cMCADs patients.We then have studied the immune response against SARS-CoV-2 and other endemic coronaviruses in these patients. We did not observe any abnormalities in the immune response either at the level of T and B lymphocytes. These findings underscore that these patients might not be at risk of severe COVID-19 as one might have feared.

Published
2021

36. Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modernera therapy: A real-life study.

Author

Debureaux, Pierre-Edouard, Harel, Stéphanie, Parquet, Nathalie, Lemiale, Virginie, Siguret, Virginie, Goubeau, Laurie, Morin, Florence, Royer, Bruno, Cuccuini, Wendy, Elessa, Dikelele, Theves, Floriane, Brignier, Anne C., Azoulay, Elie, Arnulf, Bertrand, and Talbot, Alexis

Subjects
MULTIPLE myeloma, OLDER patients, PLASMA exchange (Therapeutics), ALKYLATING agents, PROGNOSIS, WALDENSTROM'S macroglobulinemia
Abstract

Hyperviscosity syndrome (HVS) is a rare complication of newly diagnosed multiple myeloma (NDMM) related to high tumour burden. Studies about the prognosis of HVS in modern-era therapy for NDMM are missing. We investigated a retrospective cohort study of NDMM with HVS between 2011- 2021. Thirty-nine NDMM patients with HVS were included. HVS presentation was heterogeneous, with asymptomatic, mild, and neurological forms in 23%, 59%, and 18% of cases, respectively. No thrombosis or major bleeding was observed. Therapeutic plasma exchanges were used in 92% of patients, which were effective and well tolerated. No rebound effect was observed. All patients except one had at least one CRAB criterion. Most of the patients received bortezomib and high-dose steroids (95%) associated with an immunomodulatory drug (43%) or alkylating agents (42%). HVS in NDMM patients had dismal overall survival matched to multiple myeloma patient controls (without HVS) in our center (median: 3.6 vs. 7.7 years, p=0.01), as confirmed by multivariate analysis. Early deaths (in the first two months) occurred in 21% of older patients (>65 years). HVS in NDMM patients is a rare but life-threatening complication associated with high lethality in older patients and be a potential dismal prognosis factor in the modern treatment era. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response

Author

Rossignol, Julien, primary, Ouedrani, Amani, additional, Livideanu, Cristina Bulai, additional, Barete, Stéphane, additional, Terriou, Louis, additional, Launay, David, additional, Lemal, Richard, additional, Greco, Celine, additional, Frenzel, Laurent, additional, Meni, Cecile, additional, Bodemere-Skandalis, Christine, additional, Polivka, Laura, additional, Collange, Anne-Florence, additional, Hachichi, Hassiba, additional, Bouzourine, Sonia, additional, Messaoud, Djazira Nait, additional, Negretto, Mathilde, additional, Vendrame, Laurence, additional, Jambou, Marguerite, additional, Gousseff, Marie, additional, Durupt, Stéphane, additional, Lega, Jean-Christophe, additional, Durand, Jean-Marc, additional, Gaudy, Caroline, additional, Damaj, Gandhi, additional, Gourin, Marie-Pierre, additional, Hamidou, Mohamed, additional, Bouillet, Laurence, additional, Le Mouel, Edwige, additional, Maria, Alexandre, additional, Zunic, Patricia, additional, Cabrera, Quentin, additional, Vincent, Denis, additional, Lavigne, Christian, additional, Riviere, Etienne, additional, Gourguechon, Clement, additional, Brignier, Anne, additional, Lhermitte, Ludovic, additional, Molina, Thierry Jo, additional, Bruneau, Julie, additional, Agopian, Julie, additional, Dubreuil, Patrice, additional, Ranta, Dana, additional, Mania, Alexandre, additional, Arock, Michel, additional, Staropoli, Isabelle, additional, Tournilhac, Olivier, additional, Lortholary, Olivier, additional, Schwartz, Olivier, additional, Chatenoud, Lucienne, additional, and Hermine, Olivier, additional

Published
2021
Full Text
View/download PDF

40. Le traitement anti-plasmocytaire entraîne une réponse clinico-biologique durable chez les patients atteints d’un scléromyxoedème en rechute ou avec une forme extra-cutanée sévère et un sevrage des immunoglobulines intra-veineuses

Author

Theves, F., Lahuna, C., Mahévas, T., Harel, S., Royer, B., Lemiale, V., Brignier, A., Parquet, N., Jachiet, M., Bouaziz, J.D., Elessa, D., Arnulf, B., and Talbot, A.

Abstract

Le scléromyxoedeme (SM) est une mucinose primaire systémique très fréquemment associée à une gammapathie monoclonale appartenant au spectre des gammapathies monoclonales de signification clinique et cutanée. Les immunoglobulines intra-veineuses (IgIV) données à 2g/kg/cure mensuelle sont le traitement de première intention. Néanmoins, certains patients rechutent ou sont dépendants de fortes doses d’immunoglobulines, ou présentent des complications sévères extra-cutanées comme le dermato neuro-syndrome ou les atteintes cardiaques (cardiomyopathie hypertrophique).

Published
2024
Full Text
View/download PDF

41. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors.

Author

Daniella Arêas Mendes-da-Cruz, Anne Colette Brignier, Vahid Asnafi, Frederic Baleydier, Carolina Valença Messias, Yves Lepelletier, Nawel Bedjaoui, Amedée Renand, Salete Smaniotto, Danielle Canioni, Pierre Milpied, Karl Balabanian, Philippe Bousso, Stéphane Leprêtre, Yves Bertrand, Hervé Dombret, Norbert Ifrah, Mireille Dardenne, Elizabeth Macintyre, Wilson Savino, and Olivier Hermine

Subjects
Medicine, Science
Abstract

Neuropilins and semaphorins are known as modulators of axon guidance, angiogenesis, and organogenesis in the developing nervous system, but have been recently evidenced as also playing a role in the immune system. Here we describe the expression and role of semaphorin 3F (SEMA3F) and its receptor neuropilin-2 (NRP2) in human T cell precursors. NRP2 and SEMA3F are expressed in the human thymus, in both lymphoid and non-lymphoid compartments. SEMA3F have a repulsive effect on thymocyte migration and inhibited CXCL12- and sphingosine-1-phosphate (S1P)-induced thymocyte migration by inhibiting cytoskeleton reorganization prior to stimuli. Moreover, NRP2 and SEMA3F are expressed in human T-cell acute lymphoblastic leukemia/lymphoma primary cells. In these tumor cells, SEMA3F also blocks their migration induced by CXCL12 and S1P. Our data show that SEMA3F and NRP2 are further regulators of human thymocyte migration in physiological and pathological conditions.

Published
2014
Full Text
View/download PDF

43. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Author

Julie Roupret-Serzec, Stéphanie Mathis, Nathalie Parquet, Hélène Cavé, Marie-Emilie Dourthe, Delphine Chaillou, Jean Hugues Dalle, Nathalie Dhedin, Aurélie Caye-Eude, Emmanuelle Clappier, Ilhem Rahal, Valérie Guérin-El Khourouj, Florian Chevillon, Karima Yakouben, Isabelle Madelaine, Elie Azoulay, Aurélie Cabannes-Hamy, Jérôme Larghero, Audrey Grain, Jérôme Naudin, Elodie Lainey, Francoise Mechinaud, Anne Brignier, Nicolas Boissel, Emmanuelle Lesprit, Florence Rabian, André Baruchel, and Sophie Caillat-Zucman

Subjects
0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Antigens, CD19, Receptors, Antigen, T-Cell, Gastroenterology, CD19, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Antineoplastic Agents, Immunological, Refractory, Internal medicine, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, medicine, Humans, Cumulative incidence, Prospective Studies, Child, Disease burden, B-Lymphocytes, biology, business.industry, Infant, Hematology, Aplasia, medicine.disease, Prognosis, Survival Rate, Cytokine release syndrome, 030104 developmental biology, Prior Therapy, Oncology, 030220 oncology & carcinogenesis, Child, Preschool, biology.protein, Blinatumomab, Female, Neoplasm Recurrence, Local, business, medicine.drug, Follow-Up Studies
Abstract

Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30-50% of patients. Determinants for CD19pos versus CD19neg relapses are poorly characterized. We report on 51 patients with R/R BCP-ALL (median age 17 years) infused with tisagenlecleucel after lymphodepletion. Complete remission rate at D28 was 96%. Prior blinatumomab increased the risk of early failure at D28. The 18-month cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS) were 51%, 44%, and 74%, respectively, at a median follow-up of 15.5 months. Factors associated with a high tumor burden (occurrence of cytokine release syndrome) and prior blinatumomab were associated with an increased CIR, and a shorter EFS and OS. Pre-lymphodepletion high disease burden (MRD ≥ 10-2, SHR 10.4, p = 0.03) and detectable MRD at D28 (SHR 7.2, p = 0.006) correlated with an increased risk of CD19neg relapse. Low disease burden (SHR 5.3, p = 0.03) and loss of B-cell aplasia (BCA) (SHR 21.7, p = 0.004) predicted an increased risk of CD19pos relapses. These data highlight the impact of prior therapy on patient outcome. Finally, detectable MRD at D28 and loss of BCA both define patients at high risk of relapse for whom additional interventions are needed.

Published
2021

44. Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements

Author

Juliette Soret-Dulphy, Laetitia Vercellino, Anne C. Brignier, Marie-Helene Schlageter, Louis Drevon, Bruno Cassinat, Célia Belkhodja, Christine Chomienne, Nabih Maslah, Christine Dosquet, Nathalie Parquet, Jean-Jacques Kiladjian, Odno Ravdan, Stéphane Giraudier, leboeuf, Christophe, Hématopoïèse normale et pathologique : émergence, environnement et recherche translationnelle [Paris] ((UMR_S1131 / U1131)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), France Intergroupe des Syndromes Myeloproliferatifs (FMI Paris), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC Saint Louis (CIC-1427), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Hemodilution, medicine.medical_specialty, Red Cell, Anemia, business.industry, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], MEDLINE, Hematology, medicine.disease, Single Center, Cohort Studies, Text mining, Hematocrit, Internal medicine, Cohort, medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Letters to the Editor, business, Erythrocyte Volume
Abstract

International audience; No abstract available

Published
2021

45. Failure and out of Specification Manufacturing of Autologous CAR-T Cells Could be Associated with a High Concentration of Total Nucleated Cells, CD3 + Cells and Neutrophils in the Apheresis Product

Author

Cohet, Guillaume, NGO-Chin, Cedrik, Douki, Nadia, Desniaux, Marion, Cornu, Stellie, Nasone, Justine, Cras, Audrey, Faivre, Lionel, Parquet, Nathalie, Brignier, Anne, Menouche, Dehbia, Lesprit, Emmanuelle, Azar, Nabih, Belhocine, Ramdane, Madelaine, Isabelle, de JORNA, Romain, Larghero, Jerome, and Mebarki, Miryam

Published
2023
Full Text
View/download PDF

46. Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

Author

Lecornec, Nicolas, Dourthe, Marie-Emilie, Rabian, Florence, Yakouben, Karima, Chevillon, Florian, Chaillou, Delphine, Caillat-Zucman, Sophie, Cuffel, Alexis, Lesprit, Emmanuelle, Arnould, Anne, Naudin, Jérome, Roupret-Serzec, Julie, Parquet, Nathalie, Brignier, Anne, Guerin-El Khourouj, Valerie, Lainey, Elodie, Caye-Eude, Aurélie, Arfeuille, Chloe, Clappier, Emmanuelle, Mathis, Stéphanie, Chaix, Marie-Laure, Azoulay, Elie, Dalle, Jean-Hugues, Madelaine, Isabelle, Larghero, Jerome, Boissel, Nicolas, and Baruchel, André

Published
2023
Full Text
View/download PDF

48. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

Author

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, David Launay, Richard Lemal, Celine Greco, Laurent Frenzel, Cecile Meni, Christine Bodemere-Skandalis, Laura Polivka, Anne-Florence Collange, Hassiba Hachichi, Sonia Bouzourine, Djazira Nait Messaoud, Mathilde Negretto, Laurence Vendrame, Marguerite Jambou, Marie Gousseff, Stéphane Durupt, Jean-Christophe Lega, Jean-Marc Durand, Caroline Gaudy, Gandhi Damaj, Marie-Pierre Gourin, Mohamed Hamidou, Laurence Bouillet, Edwige Le Mouel, Alexandre Maria, Patricia Zunic, Quentin Cabrera, Denis Vincent, Christian Lavigne, Etienne Riviere, Clement Gourguechon, Marie Courbebaisse, David Lebeaux, Béatrice Parfait, Gérard Friedlander, Anne Brignier, Ludovic Lhermitte, Thierry Jo Molina, Julie Bruneau, Julie Agopian, Patrice Dubreuil, Dana Ranta, Alexandre Mania, Michel Arock, Isabelle Staropoli, Olivier Tournilhac, Olivier Lortholary, Olivier Schwartz, Lucienne Chatenoud, Olivier Hermine, Centre de référence des mastocytoses (CEREMAST), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence des Mastocytoses de Toulouse (CEREMAST), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), The authors would like to thank Fondation Université de Paris, AXA research fund, Fondation Hôpitaux de Paris-Hôpitaux de France, Mécénat du GH APHP. CUP, Fondation pour la Recherche en Physiologie and DMU BioPhyGen for the funding of the COVID-HOP study., ANR-20-COV1-0001,APCOD,Les cellules présentatrices d'antigènes dans la maladie de COVID-19 à résolution monocellulaire(2020), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), CHU Toulouse [Toulouse], Virus et Immunité - Virus and immunity, and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)

Subjects
PBMC, peripheral blood mononuclear cell, BMI, body mass index, T cells, B-cells, CEREMAST, Centre de Référence des Mastocytoses, CM, cutaneous mastocytosis, MMAS, monoclonal mast cell activation syndrome, PHA, phytohemagglutinin, PMSI, Programme de médicalisation des systèmes d'information, Antibodies, Viral, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, Antiviral Agents, WHO, World Health Organization, MIS, mastocytosis in the skin, HEK, human embryonic kidney, Humans, Immunology and Allergy, IFN, interferon, Mast Cells, APHP, Assistance Publique - Hôpitaux de Paris (Paris Public Hospital Group), B cells, SARS-CoV-2, T-cells, Immunity, COVID-19, ISM, indolent systemic mastocytosis, Clonal mast cell activation syndrome, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MCAS, mast cell activation syndrome, Original Article, Mast cell activation dis- orders, SSM, smoldering systemic mastocytosis, NK, natural killer, Mastocytosis, COVID-19, coronavirus disease 19, Mast cell activation disorders, cMCAD, clonal mast cell activation disorder
Abstract

International audience; BackgroundMast cells are key players in innate immunity and the TH2 adaptive immune response. The latter counterbalances the TH1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published.ObjectiveTo study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting.MethodsClinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti–SARS-CoV-2–specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies.ResultsOverall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2–specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2–specific, IFN-γ–producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden).ConclusionsPatients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ.

Published
2022

50. Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements

Author

Drevon, Louis, primary, Maslah, Nabih, additional, Soret-Dulphy, Juliette, additional, Dosquet, Christine, additional, Ravdan, Odno, additional, Vercellino, Laetitia, additional, Belkhodja, Celia, additional, Parquet, Nathalie, additional, Brignier, Anne C., additional, Schlageter, Marie-Helene, additional, Cassinat, Bruno, additional, Kiladjian, Jean-Jacques, additional, Chomienne, Christine, additional, and Giraudier, Stéphane, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results